In the absence of a submission from the holder of the marketing authorisation, elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (Stribild®) cannot be endorsed for use within NHS Wales for the treatment of HIV‑1 infection in adolescents aged 12 to < 18 years weighing ≥ 35 kg who are infected with HIV‑1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.